Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637931 | 0.82 | HSD17B10 (0.52) | NPSR1SMN1; SMN2RAB9ANPC1HSD17B10 | |
| SCHEMBL4616436 | 0.80 | TSHR (0.56) | NPSR1SMN1; SMN2TSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7408475 | 0.79 | TSHR (0.55) | NPSR1SMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL6975532 | 0.79 | HTT (0.61) | NPSR1SMN1; SMN2HSD17B10TSHRPOLB | |
| SCHEMBL13115728 | 0.78 | TSHR (0.69) | NPSR1SMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL4837994 | 0.77 | L3MBTL1 (0.65) | SMN1; SMN2ALDH1A1POLBMAPTHTT | |
| SCHEMBL639350 | 0.77 | SMN1; SMN2 (0.55) | NPSR1SMN1; SMN2RAB9ANPC1HSD17B10 | |
| SCHEMBL637930 | 0.77 | SMN1; SMN2 (0.54) | NPSR1SMN1; SMN2RAB9ANPC1HSD17B10 | |
| SCHEMBL8335930 | 0.77 | TSHR (0.69) | SMN1; SMN2RAB9ANPC1HSD17B10TSHR | |
| SCHEMBL29125701 | 0.76 | HSD17B10 (0.61) | NPSR1SMN1; SMN2RAB9ANPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7498330-B2 | 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATORIES SERVIER (FR) | 2009-03-03 | — | — | US | disclosed |
| EP-1593682-B1 | Derivatives of 4-oxo-4,6,7,8-tetrahydropyrrolo¬1,2-a pyrazine-6-carboxamides, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2007-11-07 | — | — | EP | disclosed |
| EP-1593682-A2 | Derivatives of 4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2005-11-09 | — | — | EP | disclosed |
| US-20050209234-A1 | 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | LES LABORATOIRES SERVIER (FR) | 2005-09-22 | — | — | US | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6277851-B1 | ORALLY ADMINISTERED TRYPSIN-RELATED SERINE PROTEASE INHIBITORS; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-08-21 | — | — | US | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131668-A1 | 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | F2, TBXA2R, PDGFRA | NPSR1 562/4885SMN1; SMN2 4422/4885RAB9A 3822/4885 |
| US-20050209234-A1 | 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds | F2, TBXA2R, PDGFRA | NPSR1 562/4885SMN1; SMN2 4422/4885RAB9A 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.